Advertisement
Screener

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Increase (Decrease) in Other Operating Assets and Liabilities, Net

ADAPTIVE BIOTECHNOLOGIES CORPORATION Increase (Decrease) in Other Operating Assets and Liabilities, Net

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $201.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-04

  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $103.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was $98.00K, a 1533.33% increase year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was -$137.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was $0.00.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was -$142.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was -$27.00K, a 136.99% decline from fiscal 2023.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $73.00K.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was -$169.00K, a 161.45% decline from fiscal 2021.
Period endIncrease (Decrease) in Other Operating Assets and Liabilities, Net 3 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 6 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 9 monthIncrease (Decrease) in Other Operating Assets and Liabilities, Net 12 month
2026-06-30$103.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$201.00K
10-Q · filed 2026-08-04
$64.00K
derived: sum of 3 quarters · filed 2026-08-04
$64.00K
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$98.00K
10-Q · filed 2026-05-05
-$39.00K
derived: sum of 2 quarters · filed 2026-05-05
-$39.00K
derived: sum of 3 quarters · filed 2026-05-05
-$50.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$137.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$137.00K
derived: sum of 2 quarters · filed 2026-02-26
-$148.00K
derived: sum of 3 quarters · filed 2026-08-04
-$142.00K
10-K · filed 2026-02-26
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$11.00K
derived: sum of 2 quarters · filed 2026-08-04
-$5.00K
10-Q · filed 2025-11-05
-$10.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$11.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$5.00K
10-Q · filed 2026-08-04
-$10.00K
derived: sum of 3 quarters · filed 2026-08-04
-$13.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$6.00K
10-Q · filed 2026-05-05
$1.00K
derived: sum of 2 quarters · filed 2026-05-05
-$2.00K
derived: sum of 3 quarters · filed 2026-05-05
-$23.00K
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$5.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$8.00K
derived: sum of 2 quarters · filed 2026-02-26
-$29.00K
derived: sum of 3 quarters · filed 2026-02-26
-$27.00K
10-K · filed 2026-02-26
2024-09-30-$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$24.00K
derived: sum of 2 quarters · filed 2025-11-05
-$22.00K
10-Q · filed 2025-11-05
-$25.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$21.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$19.00K
10-Q · filed 2025-08-05
-$22.00K
derived: sum of 3 quarters · filed 2026-02-26
$42.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$2.00K
10-Q · filed 2025-05-01
-$1.00K
derived: sum of 2 quarters · filed 2026-02-26
$63.00K
derived: sum of 3 quarters · filed 2026-02-26
$61.00K
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$61.00K
derived: sum of 2 quarters · filed 2026-02-26
$59.00K
derived: sum of 3 quarters · filed 2026-02-26
$73.00K
10-K · filed 2026-02-26
2023-09-30$64.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$62.00K
derived: sum of 2 quarters · filed 2024-11-07
$76.00K
10-Q · filed 2024-11-07
$72.00K
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30-$2.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$12.00K
10-Q · filed 2024-08-01
$8.00K
derived: sum of 3 quarters · filed 2025-03-03
-$60.00K
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$14.00K
10-Q · filed 2024-05-07
$10.00K
derived: sum of 2 quarters · filed 2025-03-03
-$58.00K
derived: sum of 3 quarters · filed 2025-03-03
2022-12-31-$4.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
-$72.00K
derived: sum of 2 quarters · filed 2025-03-03
-$169.00K
10-K · filed 2025-03-03
2022-09-30-$68.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$165.00K
10-Q · filed 2023-11-09
2022-06-30-$97.00K
10-Q · filed 2023-08-02
2021-12-31$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$155.00K
derived: sum of 2 quarters · filed 2024-02-29
$156.00K
derived: sum of 3 quarters · filed 2024-02-29
$275.00K
10-K · filed 2024-02-29
2021-09-30$152.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$153.00K
derived: sum of 2 quarters · filed 2022-11-03
$272.00K
10-Q · filed 2022-11-03
$333.00K
derived: sum of 4 quarters · filed 2023-02-14
2021-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$120.00K
10-Q · filed 2022-08-03
$181.00K
derived: sum of 3 quarters · filed 2023-02-14
$181.00K
derived: sum of 4 quarters · filed 2023-02-14
2021-03-31$119.00K
10-Q · filed 2022-05-04
$180.00K
derived: sum of 2 quarters · filed 2023-02-14
$180.00K
derived: sum of 3 quarters · filed 2023-02-14
$180.00K
derived: sum of 4 quarters · filed 2023-02-14
2020-12-31$61.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14
$61.00K
derived: sum of 2 quarters · filed 2023-02-14
$61.00K
derived: sum of 3 quarters · filed 2023-02-14
$276.00K
10-K · filed 2023-02-14
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$0.00
derived: sum of 2 quarters · filed 2021-11-03
$215.00K
10-Q · filed 2021-11-03
$275.00K
derived: sum of 4 quarters · filed 2022-02-15
2020-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$215.00K
10-Q · filed 2021-08-04
$275.00K
derived: sum of 3 quarters · filed 2022-02-15
$813.00K
derived: sum of 4 quarters · filed 2022-02-15
2020-03-31$215.00K
10-Q · filed 2021-05-05
$275.00K
derived: sum of 2 quarters · filed 2022-02-15
$813.00K
derived: sum of 3 quarters · filed 2022-02-15
2019-12-31$60.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15
$598.00K
derived: sum of 2 quarters · filed 2022-02-15
$597.00K
10-K · filed 2022-02-15
2019-09-30$538.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
$537.00K
10-Q · filed 2020-11-10
2019-06-30-$1.00K
10-Q · filed 2020-08-10
2018-12-31-$24.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
-$25.00K
derived: sum of 2 quarters · filed 2021-02-24
$182.00K
10-K · filed 2021-02-24
2018-09-30-$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$206.00K
10-Q · filed 2019-11-12
2018-06-30$207.00K
10-Q · filed 2019-08-13
2017-12-31-$24.00K
10-K · filed 2020-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Greenland Mines Ltd (GRML)United States$2.362B